<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034292</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TG1C-1301</org_study_id>
    <nct_id>NCT02034292</nct_id>
  </id_info>
  <brief_title>Safety Study of APD-791 With Aspirin and/or Clopidogrel</brief_title>
  <acronym>TG1C</acronym>
  <official_title>Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating safety and PK parameter of APD-791 when co-administered with aspirin and
      clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of APD791 when orally co-administered with Aspirin and Clopidogrel in healthy subjects</measure>
    <time_frame>safety review will be conducted at every end of dosing (about every 2 or 3 weeks)</time_frame>
    <description>Adverse reaction monitoring for subjective or objective symptoms Physical examination Vital signs 12-electrode ECG Laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic characteristic evaluation variable</measure>
    <time_frame>After last patient last visit. About 8month later since start of the study.</time_frame>
    <description>Non-compartmental analysis is conducted by using APD791 and its metabolite, M1 and M2 and the following pharmacokinetic evaluation variables are calculated.
Cmax0-12, Cmax,ss (Day 7 only), Cmin,ss (Day 7 only), tmax0-12, tmax,ss (Day 7 only), λz, t1/2β, AUC0-12 (Day 1 only), AUCinf, Accumulation index, CL/F, MRT, Vz/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic characteristic evaluation variable</measure>
    <time_frame>Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.</time_frame>
    <description>Pharmacodynam1) % inhibition of serotonin-stimulated platelet aggregation 2) Change in % inhibition of serotonin-stimulated platelet aggregation 3) % inhibition of TRAP-induced platelet aggregation ic characteristic evaluation variable</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>10mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 10mg Multiple dose and</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 20mg Multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 40mg Multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg MD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 60mg Multiple dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Multiple dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 120mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 240mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>320mg SD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APD791 320mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>10mg MD</arm_group_label>
    <arm_group_label>20mg MD</arm_group_label>
    <arm_group_label>40mg MD</arm_group_label>
    <arm_group_label>60mg MD</arm_group_label>
    <arm_group_label>Placebo MD</arm_group_label>
    <arm_group_label>120mg SD</arm_group_label>
    <arm_group_label>240mg SD</arm_group_label>
    <arm_group_label>320mg SD</arm_group_label>
    <arm_group_label>Placebo SD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>10mg MD</arm_group_label>
    <arm_group_label>20mg MD</arm_group_label>
    <arm_group_label>40mg MD</arm_group_label>
    <arm_group_label>60mg MD</arm_group_label>
    <arm_group_label>Placebo MD</arm_group_label>
    <arm_group_label>120mg SD</arm_group_label>
    <arm_group_label>240mg SD</arm_group_label>
    <arm_group_label>320mg SD</arm_group_label>
    <arm_group_label>Placebo SD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APD791</intervention_name>
    <arm_group_label>10mg MD</arm_group_label>
    <arm_group_label>20mg MD</arm_group_label>
    <arm_group_label>40mg MD</arm_group_label>
    <arm_group_label>60mg MD</arm_group_label>
    <arm_group_label>Placebo MD</arm_group_label>
    <arm_group_label>120mg SD</arm_group_label>
    <arm_group_label>240mg SD</arm_group_label>
    <arm_group_label>320mg SD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo SD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. a healthy adult between 20 and 45 years old at the time of visit for screening

          2. a person who is able to give written consent

          3. a person between 50 and 85 kg at the time of visit for screening

          4. a woman who is negative on a serum hCG test at the time of visit and the day before a
             trial, and who is not nursing

          5. a woman who agrees on double contraception, medically approved, from the time of visit
             for screening to 90 days after the last administration of a clinical trial drug, or
             who had a contraceptive operation no later than 120 days before visit for screening,
             or who is menopausal

          6. a man who had a contraceptive operation no later than 120 days before visit for
             screening, or who agrees on double contraception, medically approved, from the time of
             visit for screening to 90 days after the last administration of a clinical trial drug,
             and also agree not to donate sperm

          7. a person more than hemoglobin 12 g/dL at the time of screening (a woman more than
             hemoglobin 11 g/dL)

          8. a person whose vital signs were in the normal range at the time of visit for
             screening, or who is medically determined not to be clinically significant by an
             investigator

          9. a person who voluntarily decides to participate in this clinical trial and gives
             written consent on strict clinical trial compliance

         10. a person whose blood can be collected during a study period with visit for monitoring

        Exclusion Criteria:

          1. a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer
             within 90 days from the time of visit for screening

          2. a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease,
             ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or
             herniotomy) affecting the absorption of a clinical trial drug

          3. a person with the medical history of blood coagulation disorder or hemorrhagic
             diseases, or with clinically significant abnormal findings decided by a investigator
             on blood coagulation test at the time of screening

          4. a woman with the medical history of dysfunctional uterine bleeding within a year from
             the time of visit for screening

          5. a person with the medical history of epilepsy or convulsion

          6. a person with the medical history of internal organ transplant

          7. a person expected to be hard to complete a clinical trial because of surgery or
             medical procedures planned within a clinical trial period

          8. a person with the medical history of clinically significant new diseases within 30
             days from the time of visit for screening according to investigator's decision

          9. a person with hypersensitivity reaction to a drug or gelatin, or the medical history
             of clinically significant hypersensitivity reaction

         10. a person with the history of drug abuse, or with a positive reaction to a drug
             possible to be abused on urine drug screening

         11. a person with the medical history of alcohol abuse within two years from the time of
             visit for screening

         12. a person who is a smoker, or with a positive reaction on a urine nicotine test
             conducted at the time of visit for screening

         13. a person who donated whole blood within 60 days or constituents of blood within 30
             days, or received a blood transfusion within 30 days from the time of visit for
             screening

         14. a person taking other clinical trial drugs within 90 days from the time of visit for
             screening

         15. a person taking a prescription drug within 30 days, or a contraindicated drug or
             oriental medicine within 14 days from the time of visit for screening

         16. a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test,
             HIV test, syphilis test)

         17. a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper
             limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or
             creatinine more than 1.25 times of the reference upper limit(UNL)

         18. a person expected to be hard to complete a clinical trial due to physical or mental
             status according to investigator's medical decision at the time of visit for screening

         19. a person decided to be inappropriate to participate in this clinical trial according
             to investigator's medical decision on the result of laboratory tests, such as complete
             blood cell count, general chemical test, clinicochemical urinalysis, and physical
             examination, vital signs, ECG, other tests excluding exclusion criteria 17 items
             conducted before subject selection for a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>APD791</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

